SUPN(Supernus, Inc.) 的财务报表:医疗保健,特药与仿制药。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|
| 营业收入 | $901.00M | $1.09B | $1.19B | $1.24B |
| 毛利润 | $749.00M | $919.00M | $957.00M | $994.00M |
| 营业利润 | −$81.00M | −$152.00M | $38.00M | $262.00M |
| 净利润 | −$44.00M | −$126.00M | $7.00M | $210.00M |
| 经营现金流 | −$4.00M | −$300.00M | $36.00M | −$27.00M |
| 自由现金流 | −$9.00M | −$308.00M | $7.00M | −$93.00M |
| 摊薄每股收益 | $-0.32 | $-0.92 | $0.05 | $1.64 |